Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain-Reference-Cited by-同舟云学术

Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain

Published:2020-11-10 Issue:2 Volume:41 Page:329-348
ISSN:0272-4332
Container-title:Risk Analysis
language:en
Short-container-title:Risk Analysis

Author:

Kalkowska Dominika A.¹,Pallansch Mark A.²^ORCID,Wilkinson Amanda³,Bandyopadhyay Ananda S.⁴^ORCID,Konopka‐Anstadt Jennifer L.⁵,Burns Cara C.⁵,Oberste M. Steven⁵,Wassilak Steven G. F.³,Badizadegan Kamran¹^ORCID,Thompson Kimberly M.¹^ORCID

Affiliation:

1. Kid Risk, Inc. Orlando FL USA

2. National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Atlanta GA USA

3. Global Immunization Division, Center for Global Health Centers for Disease Control and Prevention Atlanta GA USA

4. Bill and Melinda Gates Foundation Seattle WA USA

5. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Atlanta GA USA

Funder

Centers for Disease Control and Prevention

Publisher

Wiley

Subject

Physiology (medical),Safety, Risk, Reliability and Quality

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/risa.13622

Reference71 articles.

1. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, July 2019–February 2020

2. Bandyopadhyay A. S.(2020a).Clinical data from novel type‐2 oral polio vaccine trials and plan for emergency use listing.Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization Geneva Switzerland March – April 2020. Retrieved fromhttps://www.who.int/immunization/sage/meetings/2019/october/Bandyopadhyay_polio_sage_october_2019.pdf?ua=1.

3. Bandyopadhyay A. S.(2020b).Summary of nOPV2 clinical data.Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization Geneva Switzerland March – April 2020. Retrieved fromhttps://www.who.int/immunization/sage/meetings/2020/april/SAGE_Slidedeck_Mar2020-Web.pdf?ua=1.

4. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine

5. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs);Expert Review of Vaccines;2024-06-07

2. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria;Vaccine: X;2024-06

3. Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine;BMC Infectious Diseases;2024-05-28

4. Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020–2024;Pathogens;2024-05-22

5. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization;Vaccine;2024-02